Salem A, Curran D, Carrico J, La EM, Lorenc S, Hicks K, Poston S, Carpenter CF. Public health impact and cost-effectiveness of recombinant zoster vaccine for vaccinating immunocompromised adults against herpes zoster in the United States. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria.

OBJECTIVES: Immunocompromised (IC) individuals are at increased risk of herpes zoster (HZ). We assessed the public health impact and cost-effectiveness of recombinant zoster vaccine (RZV) versus no vaccination against HZ for IC adults aged ≥18 years in the United States (US).

METHODS: A Markov model simulated a hypothetical cohort of the estimated 19,671 US haematopoietic stem cell transplant (HSCT) recipients in 2017 (starting age=35 years, IC duration=5 years, HZ incidence=60/1,000 patient-years, starting RZV efficacy=72.5%, RZV efficacy annual waning=9.1%). RZV was compared to no vaccination with annual cycles over 30 years for avoided HZ and postherpetic neuralgia (PHN) cases, number needed to vaccinate (NNV) to avoid 1 HZ or PHN case, quality-adjusted life years (QALYs) gained, and incremental cost-effectiveness ratios (ICERs). For RZV impact in other IC populations, Scenarios A–D assessed renal transplant recipients and patients with breast cancer, Hodgkin’s lymphoma, and HIV. Scenario E varied IC duration (1–30 years), HZ incidence (10–80/1,000 patient-years), and starting age (35, 45) simultaneously.

RESULTS: For HSCT recipients, RZV (2 doses) resulted in 38% and 63% fewer HZ and PHN cases, respectively, and 109 QALYs gained, versus no vaccination. RZV was cost-saving (dominant strategy) versus no vaccination. The NNV to avoid one HZ and PHN case was 9 and 47. For scenarios A–D, the NNV to avoid one case ranged from 5–10 for HZ and 37–91 for PHN; ICERs ranged from cost-saving to $95,972 (renal transplant recipients and patients with Hodgkin’s lymphoma, respectively). Of 60 input combinations in Scenario E, most were cost-saving; 10 resulted in ICERs >$100,000.

CONCLUSIONS: Vaccinating US IC adults with RZV would reduce HZ cases and is expected to be cost-saving for HSCT recipients and cost-effective for most other modeled IC populations, versus no vaccination. Consistent with recent Advisory Committee for Immunization Practices recommendations, these results support HZ vaccination with RZV in US IC adults.

Share on: